Abstract 1953
Background
Progastrin is abnormally released in the blood of patients with different cancers (colorectal, gastric, ovarian, breast, uterus, melanoma…), as the progastrin gene is a direct target of the WNT/ß-catenin oncogenic pathway involved in tumorigenesis of many organs (ASCO 2017, Prieur et al CCR 2017). The value of progastrin as a diagnostic, and as a therapeutic monitoring marker, was assessed in patients treated for peritoneal carcinomatosis from gastro-intestinal (GI) cancers in the prospective BIG-RENAPE study (NCT02823860).
Methods
Patients were enrolled during management of peritoneal carcinomatosis (before or after neo-adjuvant chemotherapy, or surgery) and then regularly sampled for blood. Progastrin was measured using the ELISA DECODE LAB test®. The diagnostic value of progastrin concentrations at inclusion in 190 GI cancer patients (test set) was assessed against 80 samples from French donors (control set with non-cancer subjects). The longitudinal therapeutic monitoring value of progastrin test was also investigated.
Results
The Area Under the ROC curve of prograstrin for cancer diagnosis was 0.87, 95% CI [0.83-092]. Progastrin was significantly elevated at inclusion in all GI tumor subtypes (p < 0.0001; median 3.08, 95% CI [1.15-7.23], including colo-rectal & small bowel (n = 151; median 2.78) and oeso-gastric (n = 33; median 4.75) carcinomas). During monitoring, progastrin levels decreased after neoadjuvant treatment (median value 2.20, n = 23), decrease that became significant after surgery (p < 0.0001, median value 1.57, n = 84), with patients going back to normal value and others not. A trend for better PFS was observed in patients with progastrin decline after surgery. Progastrin baseline value did not correlate with renal function.
Conclusions
Progastrin assay is a simple and inexpensive blood test exhibiting high diagnostic accuracy in patients with GI carcinomas, along with promising therapeutic longitudinal changes across sequential managements. Assessment of progastrin value as a multi-tumor screening assay, and as a monitoring test, is on-going.
Clinical trial identification
Legal entity responsible for the study
BIG-RENAPE.
Funding
ECS-Screening.
Editorial Acknowledgement
Disclosure
A. Prieur, P. Liaud, M. Flaceliere, D. Joubert: Employee: ECS-Screening. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract